Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Language
Publication year range
1.
Braz. J. Pharm. Sci. (Online) ; 60: e23542, 2024. tab, graf
Article in English | LILACS | ID: biblio-1533991

ABSTRACT

Abstract The goal of this work is to identify new fatty acid-mimetic 99mTc-complexes to be used as myocardial imaging agents that allow studying heart abnormalities in high-risk patients. In this sense, we designed a fatty acid-mimetic substructure including an amide moiety that, among other properties, could improve myocardial residence time. A diamide with a chain length of 15 atoms and porting a 6-hydrazinonicotinyl (HYNIC) chelator, and an analog with a short carbon-chain, were prepared with convergent organic synthetic procedures and radiolabeled with 99mTc using tricine as the sole coligand. The in vivo proofs of concept were performed using healthy mice. The new 99mTc-complexes were obtained with adequate radiochemical purity. The lipophilicities were in agreement with the length of the chains. While both 99mTc-complexes showed uptake in the myocardial muscle, the designed radiopharmaceutical with the longest chain length had preferential target-uptake and target-retention compared to other complexes described in the bibliography. Further studies, involving imaging assays, synthetic modifications, and assay of new coligands for 99mTc-HYNIC complexes, are currently ongoing.


Subject(s)
Animals , Female , Mice , Radiopharmaceuticals/adverse effects , Fatty Acids/agonists , Amides/adverse effects , Heart Defects, Congenital/classification
2.
Sci Rep ; 10(1): 2731, 2020 02 17.
Article in English | MEDLINE | ID: mdl-32066792

ABSTRACT

The aim of this work was to enhance the biodiesel quality and hydrocarbon content of green microalga B. braunii strain KMITL 2 cultivated outdoor under several salinity conditions in a batch production. The enhancement would be such that the microalgal biodiesel qualities met or exceeded the current standard so that it would be a good raw material for biodiesel production. The microalga production was in 300 L open oval ponds, among various salinity levels tested (0-20 ppt), 5 ppt was the best for hydrocarbon production, yielding 54.2 ± 0.9% hydrocarbon content and 5.1 ± 0.4 g L-1 biomass. As the microalga production was scaled up by cultivation in 3,675 L open raceway pond under the 5 ppt condition, the microalga yielded a bit higher hydrocarbon content (58.8 ± 2.9%) but much lower biomass (2.5 ± 0.5 g L-1). The production in both oval and raceway ponds yielded a nearly identical biodiesel property (61.06-67.42 cetane number) which exceeded the value specified in international standards. Therefore, it was concluded that B. braunii strain KMITL 2 can be batch cultivated in an open pond at optimum salinity to yield sufficient hydrocarbon and biomass for biodiesel production.


Subject(s)
Chlorophyta/drug effects , Fatty Acids/biosynthesis , Hydrocarbons/metabolism , Microalgae/drug effects , Salts/pharmacology , Biofuels , Biomass , Chlorophyta/growth & development , Chlorophyta/metabolism , Culture Media/chemistry , Culture Media/pharmacology , Fatty Acids/agonists , Humans , Hydrocarbons/agonists , Microalgae/growth & development , Microalgae/metabolism , Ponds , Salinity , Thailand
3.
Lipids Health Dis ; 16(1): 247, 2017 Dec 19.
Article in English | MEDLINE | ID: mdl-29258509

ABSTRACT

BACKGROUND: Accelerated loss of adipose tissue in cancer is associated with shorter survival, and reduced quality of life. Evidence is emerging suggesting tumour association with alterations in adipose tissue, but much less is known about drug-related mechanisms contributing to adipose atrophy. Identification of mechanisms by which tumour and cancer treatments, such as chemotherapy, affect adipose tissue are required to develop appropriate therapeutic interventions to prevent fat depletion in cancer. This pre-clinical study aimed to assess alterations in adipose tissue during the clinical course of cancer. METHODS: Fischer 344 rats bearing the Ward colorectal tumour were euthanized before chemotherapy, after 1- cycle, or 2-cycles of a combination chemotherapy consisting of Irinotecan (CPT-11) combined with 5-fluorouracil (5-FU), which recapitulates first line treatment for human colorectal cancer. Periuterine adipose tissue was isolated. Healthy rats served as a reference group. Histological analysis (hematoxylin and eosin), Real-time PCR (TaqMan) and proteomic analysis (LC-MS/MS) were performed. RESULTS: Larger adipocytes (3993.7 ± 52.6 µm2) in tumour-bearing animals compared to the reference group (3227.7 ± 36.7 µm2; p < 0.001) was associated with reduced expression of proteins involved in mitochondrial fatty acid oxidation. The presence of a tumour has a significant effect on phospholipid but not triglyceride fatty acid composition. There were greater proportions of saturated fatty acids concurrent with lower monounsaturated fatty acids within the PL fraction of adipocytes in tumour-bearing animals. Chemotherapy treatment decreased the size of adipocytes (2243.9 ± 30.4 µm2; p < 0.001) and led to depletion of n-3 polyunsaturated fatty acids in adipose tissue triglyceride. Evaluation of the proteome profile revealed decreased expression of proteins involved in ATP generation, ß-oxidation, and lipogenesis. Overall, adipose tissue may not be able to efficiently oxidize fatty acids to provide energy to maintain energy demanding pathways like lipogenesis inside the tissue. CONCLUSIONS: In conclusion, metabolic adaptations to mitochondrial impairment may contribute to diminished lipid storage capacity of adipose tissue following chemotherapy delivery.


Subject(s)
Adipocytes/drug effects , Adipose Tissue/drug effects , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Colonic Neoplasms/metabolism , Lipogenesis/drug effects , Mitochondria/drug effects , Adipocytes/metabolism , Adipocytes/pathology , Adipose Tissue/metabolism , Adipose Tissue/pathology , Animals , Camptothecin/analogs & derivatives , Camptothecin/pharmacology , Cell Size , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Disease Models, Animal , Fatty Acids/agonists , Fatty Acids/metabolism , Fatty Acids, Monounsaturated/antagonists & inhibitors , Fatty Acids, Monounsaturated/metabolism , Fatty Acids, Omega-3/antagonists & inhibitors , Fatty Acids, Omega-3/metabolism , Female , Fluorouracil/pharmacology , Humans , Irinotecan , Lipogenesis/genetics , Mitochondria/genetics , Mitochondria/metabolism , Mitochondrial Proteins/antagonists & inhibitors , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Phospholipids/metabolism , Proteome/antagonists & inhibitors , Proteome/genetics , Proteome/metabolism , Rats , Rats, Inbred F344 , Triglycerides/metabolism
4.
Cell Biochem Funct ; 35(2): 83-97, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28211084

ABSTRACT

To date, many studies have been conducted to find out the underlying mechanisms of hyperglycemia-induced complications in diabetes mellitus, attributed to the cellular pathologies of different cells-especially endothelial cells. However, there are still many ambiguities and unresolved issues to be clarified. Here, we investigated the alteration in biophysical and biochemical properties in human umbilical vein endothelial cells exposed to a high-glucose concentration (30mM), comparable to glucose content in type 2 diabetes mellitus, over a course of 120 hours. In addition to a reduction in the rate of cell viability and induction of oxidative stress orchestrated by the high-glucose condition, the dynamic of the fatty acid profile-including polyunsaturated, monounsaturated, and saturated fatty acids-was also altered in favor of saturated fatty acids. Genetic imbalances were also detected at chromosomal level in the cells exposed to the abnormal concentration of glucose after 120 hours. Moreover, the number of tip cells (CD31+ /CD34+ ) and in vitro tubulogenesis capability negatively diminished in comparison to parallel control groups. We found that diabetic hyperglycemia was associated with a decrease in the cell-cell tight junction and upregulation in vascular endothelial cadherin and zonula occludens (ZO)-1 molecules after 72 and 120 hours of exposure to the abnormal glucose concentration, which resulted in a profound reduction in transendothelial electrical resistance. The surface plasmon resonance analysis of the human umbilical vein endothelial cells immobilized on gold-coated sensor chips confirmed the loosening of the cell to cell intercellular junction as well as stable attachment of each cell to the basal surface. Our findings highlighted the disturbing effects of a diabetic hyperglycemia on either biochemical or biophysical properties of endothelial cells.


Subject(s)
Chromosome Aberrations/drug effects , Fatty Acids, Unsaturated/antagonists & inhibitors , Fatty Acids/agonists , Glucose/toxicity , Human Umbilical Vein Endothelial Cells/drug effects , Tight Junctions/drug effects , Apoptosis/drug effects , Biomarkers/metabolism , Cadherins/genetics , Cadherins/metabolism , Cell Adhesion/drug effects , Cell Survival/drug effects , Cells, Cultured , Electric Impedance , Fatty Acids/metabolism , Fatty Acids, Unsaturated/metabolism , Gene Expression , Human Umbilical Vein Endothelial Cells/metabolism , Human Umbilical Vein Endothelial Cells/ultrastructure , Humans , Hyperglycemia/metabolism , Hyperglycemia/pathology , Karyotyping , Models, Biological , Necrosis/chemically induced , Necrosis/pathology , Oxidative Stress , Tight Junctions/metabolism , Tight Junctions/ultrastructure , Zonula Occludens-1 Protein/genetics , Zonula Occludens-1 Protein/metabolism
5.
Biosci Biotechnol Biochem ; 80(6): 1223-9, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26872547

ABSTRACT

Rapamycin induces autophagy with lipid remodeling in yeast and mammalian cells. To investigate the lipid biosynthesis of Euglena gracilis, rapamycin was supplemented in comparison with two model algae, Chlamydomonas reinhardtii and Cyanidioschyzon merolae. In Euglena, rapamycin induced the reduction of chlorophylls and the accumulation of neutral lipids without deterring its cell proliferation. Its lipidomic profile revealed that the fatty acid composition did not alter by supplementing rapamycin. In Chlamydomonas, however, rapamycin induced serious growth inhibition as reported elsewhere. With a lower concentration of rapamycin, the alga accumulated neutral lipids without reducing chlorophylls. In Cyanidioschyzon, rapamycin did not increase neutral lipids but reduced its chlorophyll content. We also tested fatty acid elongase inhibitors such as pyroxasulfone or flufenacet in Euglena with no significant change in its neutral lipid contents. In summary, controlled supplementation of rapamycin can increase the yield of neutral lipids while the scheme is not always applicable for other algal species.


Subject(s)
Biofuels , Chlamydomonas reinhardtii/drug effects , Euglena gracilis/drug effects , Fatty Acids/agonists , Rhodophyta/drug effects , Sirolimus/pharmacology , Acetamides/pharmacology , Acetyltransferases/antagonists & inhibitors , Acetyltransferases/metabolism , Autophagy/drug effects , Cell Proliferation/drug effects , Chlamydomonas reinhardtii/metabolism , Chlorophyll/metabolism , Enzyme Inhibitors/pharmacology , Euglena gracilis/metabolism , Fatty Acid Elongases , Fatty Acids/biosynthesis , Isoxazoles/pharmacology , Rhodophyta/metabolism , Species Specificity , Sulfones/pharmacology , Thiadiazoles/pharmacology
6.
Cell Physiol Biochem ; 36(3): 1084-100, 2015.
Article in English | MEDLINE | ID: mdl-26112996

ABSTRACT

BACKGROUND/AIMS: Carnivores exhibit poor utilization of dietary carbohydrates and glucose intolerant phenotypes, yet it remains unclear what are the causal factors and underlying mechanisms. We aimed to evaluate excessive amino acids (AAs)-induced effects on insulin signaling, fatty acid biosynthesis and glucose metabolism in rainbow trout and determine the potential involvement of mTORC1 and p38 MAPK pathway. METHODS: We stimulated trout primary hepatocytes with different AA levels and employed acute administration of rapamycin to inhibit mTORC1 activation. RESULTS: Increased AA levels enhanced the phosphorylation of ribosomal protein S6 kinase (S6K1), S6, and insulin receptor substrate 1 (IRS-1) on Ser(302) but suppressed Akt and p38 phosphorylation; up-regulated the expression of genes related to gluconeogenesis and fatty acid biosynthesis. mTORC1 inhibition not only inhibited the phosphorylation of mTORC1 downstream targets, but also blunted IRS-1 Ser(302) phosphorylation and restored excessive AAs-suppressed Akt phosphorylation. Rapamycin also inhibited fatty acid biosynthetic and gluconeogenic gene expression. CONCLUSION: High levels of AAs up-regulate hepatic fatty acid biosynthetic gene expression through an mTORC1-dependent manner, while attenuate insulin-mediated repression of gluconeogenesis through elevating IRS-1 Ser(302) phosphorylation, which in turn impairs Akt activation and thereby weakening insulin action. We propose that p38 MAPK probably also involves in these AAs-induced metabolic changes.


Subject(s)
Amino Acids/pharmacology , Gluconeogenesis/drug effects , Hepatocytes/drug effects , Insulin/pharmacology , Lipogenesis/drug effects , Multiprotein Complexes/genetics , TOR Serine-Threonine Kinases/genetics , Trout/metabolism , Amino Acids/metabolism , Animals , Fatty Acids/agonists , Fatty Acids/biosynthesis , Gene Expression Regulation , Gluconeogenesis/genetics , Hepatocytes/cytology , Hepatocytes/metabolism , Insulin/metabolism , Insulin Receptor Substrate Proteins/genetics , Insulin Receptor Substrate Proteins/metabolism , Lipogenesis/genetics , Mechanistic Target of Rapamycin Complex 1 , Multiprotein Complexes/antagonists & inhibitors , Multiprotein Complexes/metabolism , Phosphorylation , Primary Cell Culture , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Ribosomal Protein S6 Kinases/genetics , Ribosomal Protein S6 Kinases/metabolism , Ribosomal Protein S6 Kinases, 70-kDa/genetics , Ribosomal Protein S6 Kinases, 70-kDa/metabolism , Signal Transduction , Sirolimus/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitors , TOR Serine-Threonine Kinases/metabolism , p38 Mitogen-Activated Protein Kinases/genetics , p38 Mitogen-Activated Protein Kinases/metabolism
7.
Biochim Biophys Acta ; 1841(9): 1329-35, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24960101

ABSTRACT

Macrophage polarization elicits various metabolic alterations which in turn influence the polarized phenotype. Activation of glycolytic metabolism accompanies and supports macrophage pro-inflammatory M1 polarization. In contrast, M2 polarization of murine macrophages in response to the Th2 cytokine interleukin-4 (IL-4) was linked to the up-regulation of mitochondrial oxidative metabolism and fatty acid oxidation (FAO), which was necessary for coining an IL-4-polarized phenotype. Here we investigated whether similar mechanisms operate in human macrophages stimulated with IL-4. IL-4 causes only moderate changes of mitochondrial oxidative metabolism and FAO, correlating with an unaltered expression of peroxisome proliferator-activated receptor-γ coactivator 1 α/ß (PGC-1α/ß), the master transcriptional regulators of mitochondrial biogenesis. Furthermore, attenuating FAO had no effect on IL-4-induced polarization-associated gene expression. Apparently, FAO is dispensable for IL-4-induced polarization of human macrophages, pointing to fundamental differences in the metabolic requirements of macrophage phenotype alterations between mice and humans.


Subject(s)
Interleukin-4/pharmacology , Macrophages/drug effects , Mitochondria/drug effects , Oxidative Phosphorylation/drug effects , Animals , Carrier Proteins/genetics , Carrier Proteins/metabolism , Fatty Acids/agonists , Fatty Acids/metabolism , Gene Expression Regulation , Humans , Macrophages/classification , Macrophages/cytology , Macrophages/metabolism , Mice , Mitochondria/metabolism , Oxidation-Reduction , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Primary Cell Culture , RNA-Binding Proteins , Signal Transduction , Species Specificity , Transcription Factors/genetics , Transcription Factors/metabolism
8.
Br J Pharmacol ; 166(4): 1193-210, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22364602

ABSTRACT

Disruptions of cell death signalling occur in pathological processes, such as cancer and degenerative disease. Increased knowledge of cell death signalling has opened new areas of therapeutic research, and identifying key mediators of cell death has become increasingly important. Early triggering events in cell death may provide potential therapeutic targets, whereas agents affecting later signals may be more palliative in nature. A group of primary mediators are derivatives of the highly unsaturated fatty acids (HUFAs), particularly oxygenated metabolites such as prostaglandins. HUFAs, esterified in cell membranes, act as critical signalling molecules in many pathological processes. Currently, agents affecting HUFA metabolism are widely prescribed in diseases involving disordered cell death signalling. However, partly due to rapid metabolism, their role in cell death signalling pathways is poorly characterized. Recently, HUFA-derived mediators, the resolvins/protectins and endocannabinoids, have added opportunities to target selective signals and pathways. This review will focus on the control of cell death by HUFA, eicosanoid (C20 fatty acid metabolites) and docosanoid (C22 metabolites), HUFA-derived lipid mediators, signalling elements in the micro-environment and their potential therapeutic applications. Further therapeutic approaches will involve cell and molecular biology, the multiple hit theory of disease progression and analysis of system plasticity. Advances in the cell biology of eicosanoid and docosanoid metabolism, together with structure/function analysis of HUFA-derived mediators, will be useful in developing therapeutic agents in pathologies characterized by alterations in cell death signalling.


Subject(s)
Cell Death/drug effects , Cell Membrane/drug effects , Eicosanoids/metabolism , Fatty Acids/metabolism , Membrane Microdomains/drug effects , Molecular Targeted Therapy , Signal Transduction/drug effects , Animals , Cannabinoid Receptor Agonists , Cannabinoid Receptor Antagonists , Cannabinoid Receptor Modulators/agonists , Cannabinoid Receptor Modulators/antagonists & inhibitors , Cannabinoid Receptor Modulators/metabolism , Cell Membrane/metabolism , Cyclooxygenase Inhibitors/pharmacology , Eicosanoids/agonists , Eicosanoids/antagonists & inhibitors , Fatty Acids/agonists , Fatty Acids/antagonists & inhibitors , Humans , Membrane Microdomains/metabolism , Metabolomics/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...